Neuronetics gets FDA clearance for NeuroStar as first-line adjunct for adolescent MDD (ages 15-21)

Neuronetics, Inc.

FDA cleared NeuroStar Advanced Therapy as first-line adjunct treatment for major depressive disorder in adolescents aged 15-21.
Supplemental information posted to Neuronetics IR website on March 25, 2024.
Expands NeuroStar's indicated population beyond adults to include adolescents with MDD.
No financial details, revenue guidance, or commercial launch timeline were disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.